Recent Updates
Recently added Catalysts

GW876008

Phase 2

Irritable Bowel Syndrome (IBS) | Small molecule | Gastrointestinal |GSK plc|Last Updated: Jan 31, 2018

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment133

FDA Designations

No designations recorded

Clinical trial landscape

GW876008 · 7 trials · 4 indications

Phase 2 3Phase 1 4
NCT00385099Effects Of GW876008 On The Bowel In Patients With Irritable Bowel SyndromeIrritable Colon
COMPLETED10 Analytics
NCT00397722Treatment Of Patients With Social Anxiety DisorderSocial Phobia
COMPLETED299 Analytics
NCT00421707Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel SyndromeIrritable Bowel Syndrome (IBS)
COMPLETED133 Analytics
PHASE2COMPLETED
Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome
Irritable ColonUnlock trial analytics
PHASE2COMPLETED
Treatment Of Patients With Social Anxiety Disorder
Social PhobiaUnlock trial analytics
PHASE2COMPLETED
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS)Unlock trial analytics

Study Endpoints

Primary Endpoints

Percent change from Baseline in Laser Doppler regional Rectal Mucosal Blood Flow (RMBF) measured in response to physiological stress (cold water pressor test)
Baseline (pre-dose) and Study Days 1, 2 and 3

Laser Doppler flowmetry measures changes in red cell flux using a probe that scans a fixed volume of tissue. Participants were examined in the left lateral position where DRT4 laser Doppler flow meter was placed against the rectal mucosa 10 centimeter (cm) above the lower limit of the anal margin, and pre-stress readings were taken after a period of 10 minutes of acclimatization in a room with an ambient temperature of 22 degrees Celsius. Physiological stress was evoked using the cold water pressor test. Participants were asked to place their hand and forearm into a container of ice-cold water at 0-4degree Celsius and were persuaded to maintain that position for as long as possible during the stress period of 10 minutes. Readings were then taken during pre-stress and at 5-minute intervals during the stress and recovery periods. Baseline was defined as the pre-dose assessment. Change from Baseline was calculated by subtracting the Baseline value minus the post-randomization value.

Percent Change from Baseline in Laser Doppler regional RMBF measured in response to psychological stress (dichotomous listening test)
Baseline (pre-dose) and Study Days 1, 2 and 3

Laser Doppler flowmetry measures changes in red cell flux using a probe that scans a fixed volume of tissue, an indirect measure of flow can be obtained. Participants were examined in the left lateral position with no prior bowel preparation. The laser Doppler probe (DRT4 laser Doppler flow meter) was then placed against the rectal mucosa 10 centimeter above the lower limit of the anal margin, and pre-stress readings were taken after a period of 10 minutes of acclimatization in a room with an ambient temperature of 22 degrees Celsius. The dichotomous listening test was used as a psychological stressor. At the onset of stress, folk music was played into one ear and rock music into the other ear for 10 minutes. Readings were then taken during pre-stress and at 5-minute intervals during the stress and recovery periods. Baseline was defined as the pre-dose assessment. Change from Baseline was calculated by subtracting the Baseline value minus the post-randomization value.

Change from randomization in the clinician-administered LSAS total score at the end of the treatment phase (Week 12)
Baseline (Day 0) and Week 12

The LSAS is an investigator-rated scale consisting of 48 questions concerning various social situations. The LSAS is the first psychiatric assessment at all post-screening visits. A qualified independent efficacy rater scored the participant's "fear or anxiety" and "avoidance" of social situations on 4-point scale : where, 0= None, 1= Mild, 2= Moderate, 3= Severe. Scores were recorded in participant's source documents. The LSAS total score was the sum of each of the forty-eight individual responses. Day 0 was Baseline and change from Baseline was calculated by subtracting Baseline value from Week 12 value. Data for adjusted mean and SE is presented.

Change from randomization on the LSAS Fear subscale score at Week 12
Baseline (Day 0) Week 12

The LSAS consisted of 24 fear responses. All individual items were rated on a scale 0 (none) -3 (severe) with higher scores indicating more severe fear. The LSAS fear subscale score was the sum of each of the 24 individual responses. If at least 22 items of the items making up the subscale of interest were present at a particular time point, the subscale score was calculated as Sum of non-missing items multiplied with 24/Number of non-missing items. If less than 22 of the items making up the score of interest were available for a participant at a particular time point, the subscale score was not calculated for that time point. Day 0 was Baseline and change from Baseline was calculated by subtracting Baseline value from Week 12 value. Data for adjusted mean and SE is presented.

Change from randomization on the LSAS Avoidance subscale score at Week 12
Baseline (Day 0) and Week 12

The LSAS consisted of 24 avoidance responses. All individual items were rated on a scale 0 (never) -3 (always) with higher scores indicating more severe avoidance. The LSAS avoidance subscale Score was the sum of each of the 24 individual responses. If at least 22 items of the items making up the subscale of interest were present at a particular time point, the total score was calculated as Sum of non-missing items multiplied with 24/Number of non-missing items. If less than 22 of the items making up the score of interest were available for a participant at a particular time point, the subscale score was not calculated for that time point. . Day 0 was Baseline and change from Baseline was calculated by subtracting Baseline value from Week 12 value. Data for adjusted mean and SE is presented.

Change from randomization on the Social Avoidance and Distress Scale (SADS) total score at Week 12
Baseline (Day 0) and Week 12

The SADS is a 28 item questionnaire. The total score was obtained by summing together the responses for all 28 items from the SADS questionnaire. Each individual item was rated as true or false. One point was given where items 2, 5, 8, 10, 11, 13, 14, 16, 18, 20, 21, 23, 24, 26 were marked as true and 1 point when each of the remaining items were marked as false. This gave a possible range of possible scores from 0 to 28 with higher scores indicating more severe disorder. If at least 26 of the items making up the total score were present at a particular time point, the total score was calculated as Sum of scores for non-missing items multiplied with 28/Number of non-missing items. If less than 26 of the items making up the score of interest were available for a participant at a particular time point, the total score was not calculated for that time point.

Number of Participants With Average Adequate Relief Rate During the Last 4 Weeks of the Treatment Periods (Weeks 3-6. in Period 1, Weeks 12-15 in Period 2).
Up to Day 105 (weeks 3-6. in period 1, weeks 12-15 in period 2)

For the assessment of average adequate relief rate from IBS symptoms for a participant was planned by collecting the response of a question 'In the past seven days have you had adequate relief of your IBS pain or discomfort? However, in error, the question was not collected in the IVRS system. Therefore, data for this endpoints was not collected during this study.

Number of Participants With Changes in Weekly Adequate Relief Rates During the Treatment Periods (Weeks 1-6 in Period 1 and Weeks 9-15 in Period 2).
Up to Day 105 (weeks 1-6 in period 1 and weeks 9-15 in period 2).

For the assessment of changes in weekly adequate relief rates during the treatment periods was planned by collecting the response of a question. Overall response was defined as having achieved adequate relief in last 4 weeks. However, in error, the question was not collected in the IVRS system. Therefore, data for this endpoints was not collected during this study.

Number of Participants With Adequate Relief of IBS Pain and Discomfort on All 4 of the Last 4 Weeks of the Treatment Phase Treatment Periods 1 and 2
Up to Day 105

For the assessment of average adequate relief rate from IBS symptoms for a participant was planned by collecting the response of a question whether weekly adequate relief from IBS symptoms was achieved?. However, in error, the question was not collected in the IVRS system. Therefore, data for this endpoints was not collected during this study.

Mean Global Improvement Scale (GIS) Responder Rate Over the Last Four Weeks by Regimen
Up to Day 105 (weeks 3-6 in period 1, weeks 12-15 in period 2)

The GIS is comprised of ten questions, all rated on a seven point scale ranging from substantially worse (7) to substantially improved (1). GIS assesses the participant's improvement (or worsening) as assessed by the clinician on a 7-point scale: 1: very much improved; 2: much improved; 3: minimally improved; 4: no change; 5: minimally worse; 6: much worse; or 7: very much worse for diarrhea, constipation, stool frequency, stool consistency, urgency, bloating, incomplete evacuation, and straining. Values reported are less than the minimum score on scale as the rate is the proportion of the last four weeks that the participant is a responder.

Ratings on Irritable Bowel Syndrome Quality of Life (IBSQoL) Scale
Up to Day 105 (weeks 3-6 in period 1, weeks 12-15 in period 2)

The IBSQoL is a self-report quality-of-life measure specific to IBS that can be used to assess the impact of IBS and its treatment. The IBSQoL consists of 30 statements about bowel problems, which formed 9 scales: emotional health, mental health, health belief, sleep, energy, physical functioning, diet, social role, physical role and sexual relation. All 9 scales were rated on a five-point response scale ranging from 1 (always) to 5 (never). Scores for individual items were averaged to obtain a total score for each subscale of IBSQoL. Then transformed to a 0-100 scale for ease of interpretation with higher scores indicating better IBS-specific quality of life. Transformed scale score = (raw score - lowest possible scale score)/ (scale range) X 100. The data presented for individual scale.

Differences in brain activation elicited by Matching Emotional Face Expression paradigm following single oral doses of GW876008 and lorazepam on day 1, sessions 1-4
Blood levels of GW876008 and midazolam collected on Day 1 of Session 1 and on Days 1 and 14 of Session 2.
on Day 1 of Session 1 and on Days 1 and 14 of Session 2.
Signal reductions in the amygdala during viewing of emotional faces and during abdominal pain threat as measured by the fMRI.
throughout the study
Blood levels of GW876008 collected on Day 1 at pre-dose and over 72 hours post-dose.
on Day 1 at pre-dose and over 72 hours post-dose.

Secondary Endpoints

Number of participants with adverse events (AE) and serious adverse events (SAE)
Up to Week 14
Number of participants with abnormal clinical chemistry data of clinical concern
Up to Week 14
Number of participants with abnormal hematology data of clinical concern
Up to Week 14
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
GW876008EXPERIMENTALGW876008
PlaceboPLACEBO_COMPARATORPlacebo
GW876008 20mcgEXPERIMENTALGW876008 20mcg
GW876008 200mcgEXPERIMENTALGW876008 200mcg

Interventions

NameTypeDescription
GW876008DRUG -
paroxetineDRUG -
PlaceboOTHER -
lorazepamDRUG -
midazolamDRUG -
GW876008 200mcgDRUGGW876008
GW876008 20mcgDRUGGW876008 20mcg
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion criteria: * Must have irritable bowel syndrome. Exclusion criteria: * Subjects who have been taking any medication for the treatment of irritable bowel syndrome within 6 months prior to the start of the study.

Countries:United KingdomUnited StatesCanadaFinlandGermanyNorwaySouth AfricaSweden
Unlock Eligibility Criteria

Competitive Landscape -Irritable Bowel Syndrome 12 trials (matched to "Irritable Bowel Syndrome (IBS)")

Frequently asked questions about GW876008

What is GW876008 used for?

GW876008 is an investigational small molecule that has been studied in patients with irritable bowel syndrome (IBS) and in healthy subjects. Clinical trials have also explored its effects in social phobia and irritable colon, though the primary completed studies focused on IBS and healthy volunteer assessments.

Who makes GW876008?

GW876008 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. GSK has sponsored the clinical trials of this investigational drug.

What phase is GW876008 in?

GW876008 is an investigational drug that has completed Phase 1 and Phase 2 clinical trials. It is not approved by regulatory authorities and remains in clinical development. The most advanced completed study was a Phase 2 trial in irritable bowel syndrome.

What clinical trials is GW876008 in?

GW876008 has completed three clinical trials. NCT00421707 was a Phase 2 study in patients with irritable bowel syndrome. NCT00423761 and NCT00424697 were Phase 1 studies in healthy subjects, and NCT00429728 was a Phase 1 study investigating metabolism in smokers versus non-smokers.

Is GW876008 the same as any other drug?

GW876008 is the investigational code name for this compound developed by GSK. No alternative brand names or other designations have been publicly associated with this drug in the clinical trial records.

What does GW876008 target?

The molecular target of GW876008 has not been disclosed in the available clinical trial information. The drug is a small molecule being studied for its effects on irritable bowel syndrome and emotional processing in healthy subjects, but its specific biological mechanism is not publicly detailed.